TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Positive predictive value of Waters' projections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentration of Lp(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of 25-hydroxyvitamin D3 with 24,25-dihydroxyvitamin D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placental mRNA abundance of vitamin D metabolic components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production and secretion of 25-hydroxyvitamin D3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline Viral Load (BVL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subsequent Viral Load (SVL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total PANSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PANSS negative subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (C max) of felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of felodipine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of fluid aspirated
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of aspirations performed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma NO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Verbal fluency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Conjunctival redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to onset of neuromuscular block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month target lesion revascularization (TLR)-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in at least one PA level according to the IPAQ categorical score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in upper limb pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in neck disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lean body mass gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diminished brain activity induced by motivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic accuracy of malignant thyroid nodules
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: choice reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: immediate word recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: delayed word recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Contrast-to-noise ratio of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Figure of merit of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timing of angioplasty initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: minimum SaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean SaO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in cardiovascular risk profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ruptured uterus
Endpoint domain: Adverse events/effects
Primary endpoint: predictive value of risk assessment scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pressure ulcer development prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Incidence of flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Overall corticosteroid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of digital lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of attacks of Raynaud's phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of attacks of Raynaud's phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breast cancer followed by death
Endpoint domain: Mortality/survival
Primary endpoint: Diabetes requiring insulin
Endpoint domain: Mortality/survival
Primary endpoint: Aseptic loosening of femoral and tibial components
Endpoint domain: Adverse events/effects
Primary endpoint: Revision of femoral and tibial components
Endpoint domain: Adverse events/effects
Primary endpoint: Onset time of neuromuscular block (NMB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Valve related morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of successful prehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of PPC(®)‐PCMH™ Level 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving LDL-C target goal (< 115 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in total cholesterol (TC) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total cost of modified TC treatment and other services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: days with headaches
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence regarding rate and extent of absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance of treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Severe RVGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Participants' accuracy at counting target audiovisual events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Smoking quit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of sesamoid position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Correction of hallux valgus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Correction of intermetatarsal angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Aerobe/anaerobe ratio of sub‐ and supragingival colony forming units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorectal cancer screening completion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommendations for colorectal cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of child learning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rates of child social-emotional behaviour
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of eyes showing resolution of polypoidal lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cefazolin tissue concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspiration detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of lymph nodes retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: bothersomeness of back symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-report disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: hyperphosphataemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hypocalcaemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tolerance of NaP
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean daytime systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean daytime diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Contrast enhancement in screening upper abdominal CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NICU admission rate
Endpoint domain: Adverse events/effects
Primary endpoint: Gestational Diabetes Mellitus (GDM) prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of bladder overactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of bladder overactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma concentrations of soluble tumor necrosis factor receptors (sTNF-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma concentrations of interleukin-6 (IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Moderate to severe pain (VAS > 5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Requirement of additional analgesic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Recovery of motor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sinus node dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decline in verbal memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of profound motor block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Eye opening time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor movement time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum Uric Acid (SU) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: body water volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweat loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of major depression (MD) in the first year postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median number of days of pVL suppression to below 500 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative risk of an increase in pVL above 500 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk of virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oocyte damage after ICSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal fertilization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cleavage rates after ICSI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all-cause death, stroke, or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Rates of chart‐documented PSA discussions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of PSA testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA knowledge scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caudal block success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean distribution count of contrast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI OMERACT synovitis score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased mortality
Endpoint domain: Mortality/survival
Primary endpoint: Good recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average hospital discharge time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: DBP reactivity to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resting blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mood responsiveness to treatment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of PSA tests not carried out as SHI services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pain with IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glomerular filtration rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Basic recovery rate of FNFI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endogenous glucose rate of appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in symptoms of irritable behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative survival free of death or major events
Endpoint domain: Mortality/survival
Primary endpoint: percentage of reintervention
Endpoint domain: Adverse events/effects
Primary endpoint: SF-36 Physical Component Summary score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neck and arm pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants developing a new pressure ulcer of grade 2 or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: mean hospital bed days per patient per year
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: urinary calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Conversion to normal sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arrhythmias after cardioversion
Endpoint domain: Adverse events/effects
Primary endpoint: Team performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Information sharing
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Rate of A (sev) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement of anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increases of daily spiritual experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Viral DNA shedding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: VALS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of sexual risk among adolescents
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical response prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intubation success on the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analog scale score for ease of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stiffness index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma non‐esterified fatty acids concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of pain from injections
Endpoint domain: Adverse events/effects
Primary endpoint: Dynamic pain scores (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: discharge rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of exercise-induced bronchoconstriction (EIB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postexercise breathlessness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PAQLQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Noradrenaline spillover rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adrenaline secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intraarterial blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean training time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Function improvement (DASH score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing of anal fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proteinuria (PU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial Infarction (MI) rate
Endpoint domain: Mortality/survival
Primary endpoint: contrast sensitivity at 2.5 degrees visual angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glare sensitivity at 4.0 degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of locoregional disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Psychiatric Rating Scale (BPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average gestational age at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: CSA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical summary component of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IRA stenosis detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MVD detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of subjects demonstrating a 10‐mm Hg increase in IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Mean number of weeks required to achieve a 10‐mm Hg response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to perform a satisfactory postoperative eye examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forceps path lengths
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Skeletal transverse expansion of nasal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal steady-state IM temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year change in central SE myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Survival (OS) values
Endpoint domain: Mortality/survival
Primary endpoint: WOMAC stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: WOMAC function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PIVKAII detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PIVKAII levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Center of Pressure (COP) distance covered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COP velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pressure under ipsilateral ischial tuberosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life impact of stress urinary incontinence
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Net monetary benefit per caregiver
Endpoint domain: Resource use
Endpoint subdomain: Other resource use